The animal health division of Eli Lilly is to acquire a plant in Ireland after today announcing Lilly has signed an agreement to acquire the European rights to a portfolio of some Pfizer animal health products.
As part of a deal, Elanco will take over the manufacturing facility in Sligo, currently used in the production of animal vaccines. As part of the deal, all Sligo employees will be offered positions with Elanco.
The products - including vaccines, parasiticides and feed additives - have been marketed by Pfizer and Wyeth.
“The addition of this attractive portfolio of products and a world-class manufacturing facility is a natural fit for Elanco and positions us well for sustained growth,” said Jeff Simmons, president of Elanco. “Through this acquisition, we will expand and diversify our European presence with new market-leading products," he said.
The European Commission requested that Pfizer divest these products as a result of Pfizer’s acquisition last year of Wyeth, including Wyeth’s Fort Dodge Animal Health business.
Under the terms of the agreement, Lilly will acquire European rights to a portfolio of marketed products, as well as the biological manufacturing facility in Sligo, Ireland. In return, Pfizer will receive an undisclosed upfront payment.
Closing of the transaction is contingent upon clearance from European regulatory authorities and other closing conditions.